These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 2044259)
1. Drug intervention trials in dyslipidemia: the past and the future. Dujovne CA Clin Cardiol; 1991 Feb; 14(2 Suppl 1):I48-52. PubMed ID: 2044259 [TBL] [Abstract][Full Text] [Related]
2. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias. Yee HS; Fong NT Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596 [TBL] [Abstract][Full Text] [Related]
3. Selections from current literature: the fight over fat: is pharmacological lipid lowering useful for coronary primary prevention? Green L Fam Pract; 1997 Oct; 14(5):411-5. PubMed ID: 9472378 [TBL] [Abstract][Full Text] [Related]
4. Management of lipids in primary and secondary prevention of cardiovascular diseases. Lavie CJ; Gau GT; Squires RW; Kottke BA Mayo Clin Proc; 1988 Jun; 63(6):605-21. PubMed ID: 3287024 [TBL] [Abstract][Full Text] [Related]
5. Should pediatric patients with hyperlipidemia receive drug therapy? Bhatnagar D Paediatr Drugs; 2002; 4(4):223-30. PubMed ID: 11960511 [TBL] [Abstract][Full Text] [Related]
6. Future directions in lipid therapies. Ansell B Adv Ther; 2002; 19(2):61-72. PubMed ID: 12069369 [TBL] [Abstract][Full Text] [Related]
7. Advances in drug treatment of dyslipidemia: focus on atorvastatin. Davignon J Can J Cardiol; 1998 May; 14 Suppl B():28B-38B. PubMed ID: 9627539 [TBL] [Abstract][Full Text] [Related]
8. New lipid lowering drugs and new effects of old drugs. Dujovne CA Curr Opin Lipidol; 1997 Dec; 8(6):362-8. PubMed ID: 9412777 [TBL] [Abstract][Full Text] [Related]
10. Perspectives in the treatment of dyslipidemias in the prevention of coronary heart disease. Borgia MC; Medici F Angiology; 1998 May; 49(5):339-48. PubMed ID: 9591525 [TBL] [Abstract][Full Text] [Related]
11. [Overviews of fibrate]. Tada N Nihon Rinsho; 2001 Mar; 59 Suppl 3():609-17. PubMed ID: 11347141 [No Abstract] [Full Text] [Related]
12. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. Evans M; Roberts A; Davies S; Rees A Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326 [TBL] [Abstract][Full Text] [Related]
13. [Nicotinic acid and the derivative]. Ogaki S; Matsushima T Nihon Rinsho; 2001 Mar; 59 Suppl 3():637-41. PubMed ID: 11347146 [No Abstract] [Full Text] [Related]
14. Non-adherence to lipid-lowering therapies: a need for more studies to evaluate reasons for medication non-adherence. Wong MC; Wang HH; Liu KS Int J Clin Pract; 2011 Dec; 65(12):1321-2. PubMed ID: 22093540 [No Abstract] [Full Text] [Related]
15. Niacin as a component of combination therapy for dyslipidemia. Miller M Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785 [TBL] [Abstract][Full Text] [Related]
16. [Hyperlipidemia in the elderly]. Kawano M Nihon Rinsho; 2002 May; 60(5):1017-23. PubMed ID: 12029980 [TBL] [Abstract][Full Text] [Related]
17. Current, new and future treatments in dyslipidaemia and atherosclerosis. Chong PH; Bachenheimer BS Drugs; 2000 Jul; 60(1):55-93. PubMed ID: 10929930 [TBL] [Abstract][Full Text] [Related]
18. Choosing the right lipid-regulating agent. A guide to selection. Farmer JA; Gotto AM Drugs; 1996 Nov; 52(5):649-61. PubMed ID: 9118815 [TBL] [Abstract][Full Text] [Related]
19. Recent developments in the treatment of atherosclerosis. Brahmkshatriya PS; Jani MH; Chhabria MT J Enzyme Inhib Med Chem; 2006 Feb; 21(1):1-15. PubMed ID: 16570499 [TBL] [Abstract][Full Text] [Related]
20. [Antilipemic agents in combined therapy]. Márk L; Császár A Orv Hetil; 2002 Aug; 143(34):1973-8. PubMed ID: 12422650 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]